An immune stimulatory approach to vaccination against coronavirus
| Reference number | |
| Coordinator | ISR Immune System Regulation AB |
| Funding from Vinnova | SEK 3 593 382 |
| Project duration | December 2020 - May 2022 |
| Status | Completed |
| Venture | EUREKA covid-19 call 2 |
| Call | Innovative solutions for increased preparedness for the next pandemic |
Important results from the project
The project´s goal was to gather the scientific evidence and document that our novel vaccine is ready for human trials. We have prepared cell banks and produced the antigen for clinical trial. We have tested several adjuvants and selected one with the highest efficiency, proven safety and reasonable price. The animal studies and toxicology tests proved the vaccine’s efficiency and provided a safety profile to define the vaccine’s application in human trials. Regulatory documentation has been submitted and ethical approval for the clinical trial has been achieved.
Expected long term effects
A general result of the project is a positive outcome of the vaccine candidate assessment. We have chosen an appropriate antigen, adjuvant, inhaler, vaccine formulation and administration route. As a final step we have identified partners for clinical trials and prepared the clinical protocol. An ultimate outcome is that we can continue the validation of the vaccine candidate in human clinical trials, which we have achieved ethical approval for.
Approach and implementation
The project was divided into 6 work packages that corresponded to different activities performed either by ISR or Icosagen. All WPs were completed on time. In general, we can conclude that the project setup (consortium of ISR and Icosagen supported by subcontractors) and the planning of the tasks was fitted to the purposes of the project and we were able to deliver high-quality results on time.